60 F
New York
Friday, May 7, 2021

Why Biogen Inc [NASDAQ: BIIB] Stock Is Jumping?

Must read

Coinbase Pro Announces it will be Listing Internet Computer’s ICP

Coinbase Pro cryptocurrency exchange has disclosed that it has decided to list ICP once it goes live. ICP is the governance token of the...

WISeKey [NASDAQ: WKEY] Gets Investment to finance its TrustNFT.IO NFT Platform

WISeKey International Holding AG disclosed Friday that it has inked a term-sheet to enter into an unsecured short-term loan and the issuance and...

Moderna [NASDAQ: MRNA] Inks Supply Agreement with Switzerland

Moderna, Inc. disclosed that it has inked a supply agreement on Thursday with the Swiss Federal Government. As per the agreement, Moderna Inc...

TeraBlock Will Have its Own BSCPad IDO Soon

TeraBlock which is a project making a platform for automated cryptocurrency portfolio management disclosed that it is preparing for an initial DEX offering (IDO)...

Shares of Biogen Inc. [NASDAQ: BIIB] rocketed 43.97% as the company gained 43.97% on the trading session of Wednesday. It was reported that the Alzheimer drug of the company will soon receive the approval of the US Food and Drug Administration (FDA).

FDA Panel has found enough evidence to support the Alzheimer’s drug of the company. The independent committee of the FDA’s expert will assess the efficacy of a drug on Friday. Committee will give suggestions to the agency about the approval of the drug.

Shares of Biogen Inc. [NASDAQ: BIIB] jumped 43.97% as the company gained 108.62% during the trading session of Wednesday. It had a trading volume of 14.59 million as compared to the average volume of 1.40 million.

In the past 52-weeks of trading, this company’s stock has fluctuated between the 52-weeks low range of $243.25 and a high range of 374.99.

Turning our focus on its liquidity, it has a current ratio of 2.10 and a quick ratio of 1.80. Furthermore, this company has a total market capitalization of 53.29 billion at the time of writing.

Aducanumab is an antibody that is developed to remove amyloid plaques from the brain. The drug analyzer of the FDA commented that the one trial of Aducanumab showed promising results.

Nearly 6 million and millions of people around the globe are experiencing this disease. Biogen Inc. revealed that it has projected that 1.5 million people are the candidates for this drug.

More articles

Latest article

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Shares of Chiasma, Inc. surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March...

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

NeoGenomics, Inc. revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing...

R1 RCM [NASDAQ: RCM] Announces Acquisition of VisitPay

R1 RCM Inc. disclosed Tuesday that it has decided to purchase VisitPay. The firm has inked an agreement to buy VisitPay for nearly...

Binance Coin Makes History as its Market Cap Reach $100 Billion

The market capitalization of Binance set new records as the exchange token of Binance and the native asset of Binance Smart Chain (BSC) touched...

Precipio [NASDAQ: PRPO] Roll Out Rapid COVID-19 Antibody test on Amazon Platform

Shares of Precipio, Inc. skyrocketed 40.35% during the trading session of Monday. The strong performance of the firm has highlighted the positive sentiments...

TechX Ink Deal to Buy Fiat-to-Crypto Merchant Services Gateway XPort Digital

TechX Technologies Inc disclosed Monday that it has bought fiat-to-crypto merchant services gateway XPort digital. The firm has bought a 100% stake in XPort...

Lockheed [NYSE: LMT] Present F-35 Best and Final Offer to Finnish Government

Lockheed Martin Corporation disclosed that it has presented F-35 best and final offer (BAFO) on April 29, 2021, to the Finnish government. It...

Clene [NASDAQ: CLNN] Gets Two Patent Notice of Allowances

Clene Inc. disclosed that Clene Nanomedicine, Inc. U.S. Patent and Trademark Office has provided Notices of Allowance for two significant patent applications. Clene...